To the Editor: Menopausal hormone therapy.

Cleve Clin J Med

Director, Center for Specialized Women's Health, Cleveland Clinic, Cleveland, OH, USA.

Published: November 2016

Download full-text PDF

Source
http://dx.doi.org/10.3949/ccjm.83c.11001DOI Listing

Publication Analysis

Top Keywords

editor menopausal
4
menopausal hormone
4
hormone therapy
4
editor
1
hormone
1
therapy
1

Similar Publications

Background: Labial adhesion (LA) is a total or partial labial fusion mostly seen in pre-pubertal children and is rare in premenopausal and postmenopausal periods. This review aimed to evaluate risk factors for labial fusion and the recurrence rate following surgical intervention in postmenopausal women.

Methods: According to PRISMA guidelines, international databases including Embase, World Cat, Web of Science, Scopus, Dimension, Open Grey, Cochrane, Google Scholar, and also PubMed gateway for PMC and MEDLINE were searched.

View Article and Find Full Text PDF

Background: Osteoporosis is a degenerative disease of bone metabolism. The epidemiology of osteoporosis varies by age, sex, and geography. There is a lack of information on the prevalence of osteoporosis among Chinese adults.

View Article and Find Full Text PDF

Aging remains the foremost risk factor for cardiovascular and cerebrovascular diseases, surpassing traditional factors in epidemiological significance. This review elucidates the cellular and molecular mechanisms underlying vascular aging, with an emphasis on sex differences that influence disease progression and clinical outcomes in older adults. We discuss the convergence of aging processes at the macro- and microvascular levels and their contributions to the pathogenesis of vascular diseases.

View Article and Find Full Text PDF

Cardiovascular disease (CVD) is a leading cause of death in women and risk of development is greatly increased following menopause. Menopause occurs over several years and is associated with hormonal changes, including a reduction in estradiol and an increase in follicle-stimulating hormone. This hormonal shift may result in an increased risk of developing abdominal adiposity, insulin resistance, dyslipidemia, vascular dysfunction, hypertension, type 2 diabetes mellitus (T2DM), metabolic dysfunction-associated fatty liver disease (MAFLD), and metabolic syndrome (MetS).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!